ARCTURUS THERAPEUTICS HOLDINGS INC. Operating Income
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Operating Income of -$25.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for the quarter ending 2026-06-30 was -$25.55M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for the quarter ending 2026-03-31 was -$28.93M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for the quarter ending 2025-12-31 was -$31.31M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for the quarter ending 2025-09-30 was -$16.51M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for fiscal 2025 was -$76.26M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for fiscal 2024 was -$95.67M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for fiscal 2023 was -$78.20M, a 742.24% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating income (loss) for fiscal 2022 was $12.18M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$25.55M 10-Q · filed 2026-08-06 | -$54.48M 10-Q · filed 2026-08-06 | -$85.78M derived: sum of 3 quarters · filed 2026-08-06 | -$102.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$28.93M 10-Q · filed 2026-05-07 | -$60.24M derived: sum of 2 quarters · filed 2026-05-07 | -$76.75M derived: sum of 3 quarters · filed 2026-05-07 | -$88.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$31.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$47.82M derived: sum of 2 quarters · filed 2026-03-03 | -$59.44M derived: sum of 3 quarters · filed 2026-08-06 | -$76.26M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$16.51M 10-Q · filed 2025-11-12 | -$28.13M derived: sum of 2 quarters · filed 2026-08-06 | -$44.95M 10-Q · filed 2025-11-12 | -$78.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$11.62M 10-Q · filed 2026-08-06 | -$28.44M 10-Q · filed 2026-08-06 | -$61.84M derived: sum of 3 quarters · filed 2026-08-06 | -$72.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$16.83M 10-Q · filed 2026-05-07 | -$50.22M derived: sum of 2 quarters · filed 2026-05-07 | -$60.96M derived: sum of 3 quarters · filed 2026-05-07 | -$82.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$33.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$44.13M derived: sum of 2 quarters · filed 2026-03-03 | -$65.26M derived: sum of 3 quarters · filed 2026-03-03 | -$95.67M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$10.74M 10-Q · filed 2025-11-12 | -$31.86M derived: sum of 2 quarters · filed 2025-11-12 | -$62.27M 10-Q · filed 2025-11-12 | -$80.55M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$21.13M 10-Q · filed 2025-08-11 | -$51.54M 10-Q · filed 2025-08-11 | -$69.81M derived: sum of 3 quarters · filed 2026-03-03 | -$89.12M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$30.41M 10-Q · filed 2025-05-12 | -$48.68M derived: sum of 2 quarters · filed 2026-03-03 | -$68.00M derived: sum of 3 quarters · filed 2026-03-03 | -$123.37M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$37.59M derived: sum of 2 quarters · filed 2026-03-03 | -$92.96M derived: sum of 3 quarters · filed 2026-03-03 | -$78.20M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$19.31M 10-Q · filed 2024-11-07 | -$74.69M derived: sum of 2 quarters · filed 2024-11-07 | -$59.93M 10-Q · filed 2024-11-07 | $61.52M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$55.37M 10-Q · filed 2024-08-05 | -$40.62M 10-Q · filed 2024-08-05 | $80.83M derived: sum of 3 quarters · filed 2025-03-06 | $44.03M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $14.76M 10-Q · filed 2024-05-08 | $136.21M derived: sum of 2 quarters · filed 2025-03-06 | $99.40M derived: sum of 3 quarters · filed 2025-03-06 | $77.31M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $121.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $84.64M derived: sum of 2 quarters · filed 2025-03-06 | $62.56M derived: sum of 3 quarters · filed 2025-03-06 | $12.18M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$36.81M 10-Q · filed 2023-11-14 | -$58.90M derived: sum of 2 quarters · filed 2023-11-14 | -$109.28M 10-Q · filed 2023-11-14 | -$146.92M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$22.09M 10-Q · filed 2023-08-07 | -$72.47M 10-Q · filed 2023-08-07 | -$110.11M derived: sum of 3 quarters · filed 2023-08-07 | -$163.93M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$50.38M 10-Q · filed 2023-05-09 | -$88.02M derived: sum of 2 quarters · filed 2023-05-09 | -$141.84M derived: sum of 3 quarters · filed 2023-05-09 | -$195.56M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$37.65M 10-K · filed 2022-03-01 | -$91.47M derived: sum of 2 quarters · filed 2022-11-09 | -$145.19M derived: sum of 3 quarters · filed 2022-11-09 | -$202.85M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$53.82M 10-Q · filed 2022-11-09 | -$107.54M derived: sum of 2 quarters · filed 2022-11-09 | -$165.21M 10-Q · filed 2022-11-09 | -$196.29M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$53.72M 10-Q · filed 2022-08-09 | -$111.39M 10-Q · filed 2022-08-09 | -$142.47M derived: sum of 3 quarters · filed 2022-08-09 | -$163.41M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$57.67M 10-Q · filed 2022-05-09 | -$88.75M derived: sum of 2 quarters · filed 2022-05-09 | -$109.69M derived: sum of 3 quarters · filed 2022-05-09 | -$119.73M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$31.08M 10-K · filed 2022-03-01 | -$52.02M derived: sum of 2 quarters · filed 2022-03-01 | -$62.06M derived: sum of 3 quarters · filed 2022-03-01 | -$71.52M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$20.94M 10-K · filed 2022-03-01 | -$30.98M derived: sum of 2 quarters · filed 2022-03-01 | -$40.44M 10-Q · filed 2021-11-09 | -$51.26M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$10.04M 10-K · filed 2022-03-01 | -$19.50M 10-Q · filed 2021-08-10 | -$30.32M derived: sum of 3 quarters · filed 2022-03-01 | -$37.94M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$9.46M 10-K · filed 2022-03-01 | -$20.28M derived: sum of 2 quarters · filed 2022-03-01 | -$27.89M derived: sum of 3 quarters · filed 2022-03-01 | -$28.47M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$10.82M 10-K · filed 2021-03-01 | -$18.43M derived: sum of 2 quarters · filed 2021-03-01 | -$19.00M derived: sum of 3 quarters · filed 2021-03-01 | -$25.51M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$7.62M 10-K · filed 2021-03-01 | -$8.19M derived: sum of 2 quarters · filed 2021-03-01 | -$14.70M 10-Q · filed 2020-11-09 | -$15.41M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$572.00K 10-K · filed 2021-03-01 | -$7.08M 10-Q · filed 2020-08-10 | -$7.79M derived: sum of 3 quarters · filed 2021-03-01 | -$12.15M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$6.51M 10-K · filed 2021-03-01 | -$7.22M derived: sum of 2 quarters · filed 2021-03-01 | -$11.57M derived: sum of 3 quarters · filed 2021-03-01 | -$21.65M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$711.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$5.07M derived: sum of 2 quarters · filed 2021-03-01 | -$15.14M derived: sum of 3 quarters · filed 2021-03-01 | -$21.81M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$4.36M 10-Q · filed 2019-11-08 | -$14.43M derived: sum of 2 quarters · filed 2019-11-08 | -$21.10M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | -$10.07M 10-Q · filed 2019-08-14 | -$16.74M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |